HROW — HARROW, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1360214 ·
Last close
$29.52
Market Cap
$1.11B
52W High
$54.85
52W Low
$25.76
ADV30
695,123
Next earnings
2026-11-09
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 99,297,000 74,903,000 11,471,000 9,757,000 443,021,000 75,336,000 414,187,000
Jun 2026 70,661,000 50,363,000 -11,007,000 -17,270,000 416,816,000 83,889,000 401,971,000
Mar 2026 44,203,000 27,045,000 -22,080,000 -27,602,000 419,543,000 94,644,000 391,192,000
Dec 2025 89,092,000 70,624,000 15,591,000 6,626,000 399,482,000 72,927,000 347,391,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,952,000
Investing CF
$-23,873,000
Financing CF
$43,871,000
CapEx
$-19,515,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.78
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-191,639,000
Inventory
$19,220,000
Receivables
$155,308,000
ST Investments
—
EBIT TTM
$-1,033,000
Pretax Income TTM
$-24,187,000
Interest Exp TTM
$23,154,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$303,252,992
EBITDA
$15,743,000
Free Cash Flow
$-34,198,876
Enterprise Value
$1,354,194,816
Total Cash
$76,805,000
Total Debt
$300,856,000
Shares Out
37,533,160
Trailing EPS
$-0.81
Book Value
$0.78
ROE
-75.5%
ROA
-0.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 272,303,000 30,515,000 -5,139,000 399,482,000 347,391,000 52,446,000 43,864,000
Dec 2024 199,614,000 9,075,000 -17,481,000 388,971,000 319,674,000 69,652,000 -22,202,000
Dec 2023 130,193,000 811,000 -24,411,000 312,164,000 241,753,000 70,766,000 3,840,000
Dec 2022 88,595,000 1,919,000 -14,086,000 157,378,000 130,138,000 27,595,000 1,705,000

TTM Snapshot

Revenues TTM
$275,594,000
NetIncome TTM
$-37,226,000
OpCashFlow TTM
—
Assets (Latest)
$416,816,000
Forward EPS
$2.09

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $39.00 · spot: $32.16 · call volume: 1,897 · put volume: 94
Expected Move to 2027-04-16: ±$9.40 (29.23%) — implied range $22.76 – $41.56 · ATM straddle on $32.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. $1.09B $7.28 —
CMPS COMPASS Pathways plc $1.13B $7.98 —
OPK OPKO HEALTH, INC. $1.20B $1.62 —
MTRI InMed Pharmaceuticals Inc. $1.02B $17.50 —
SLNCF Silence Therapeutics plc $1.22B $6.53 —

News headlines (Yahoo Finance, 1h cache)

Harrow (HROW) Stock Still Looks Undervalued As Its 229% Three Year Run Continues
2026-11-13 13:10 · Yahoo
Harrow to Participate in Two Investor Conferences in November
2026-11-12 12:00 · Yahoo
Harrow Inc (HROW) Q3 2026 Earnings Call Highlights: Record Revenue of $99. ...
2026-11-11 07:04 · Yahoo
Harrow (HROW) Q3 2026 Earnings Call Transcript
2026-11-10 20:34 · Yahoo
Harrow Q3 Earnings Call Highlights
2026-11-10 15:15 · Yahoo
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say
2026-11-09 23:00 · Yahoo
Harrow (HROW) Q3 Earnings Lag Estimates
2026-11-09 22:35 · Yahoo
Harrow: Q3 Earnings Snapshot
2026-11-09 21:33 · Yahoo
Harrow (HROW) Launches HarrowRx, Is The Stock Still Undervalued?
2026-11-07 14:12 · Yahoo
Learn Why The Bull Case For Harrow (HROW) Could Change Following Pharmacy Platform Launch
2026-11-05 02:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.